登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 广州洁特生物过滤股份有限公司（以下简称"公司"）于2025年12月29日召开第四届董事会第二十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份的议案》，同意公司使用自有资金以集中竞价 交易方式回购公司股份。本次回购的股份将在未来适宜时机用于员工持股计划或股权激励。回购资金总 金额不低于人民币1,500万元（含）且不超过人民币3,000万元（含），回购股份价格不超过人民币25.32 元/股（含），回购股份期限为自公司董事会审议通过回购方案之日起不超过12个月。 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引第 7 号一一回购股份》等相 关规定，现将公司截至上月末回购股份的进展情况公告如下： 截至2026年1月31日，公司通过上海证券交易所系统以集中竞价交易方式已回购公司股份272,799股，占 目前公司总股本140,364,345股的比例为0.19%，回购成交 ...

具体内容详见公司2025年12月31日披露于上海证券交易所（www.sse.com.cn）的《关于以集中竞价交易 方式回购股份方案的公告暨回购报告书》（公告编号：2025-072）。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688026 证券简称：洁特生物 公告编号：2026-007 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 广州洁特生物过滤股份有限公司（以下简称"公司"）于2025年12月29日召开第四届董事会第二十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份的议案》，同意公司使用自有资金以集中竞价 交易方式回购公司股份。本次回购的股份将在未来适宜时机用于员工持股计划或股权激励。回购资金总 金额不低于人民币1,500万元（含）且不超过人民币3,000万元（含），回购股份价格不超过人民币25.32 元/股（含），回购股份期限为 ...

Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is actively involved in legal disputes and has made significant investments in a new industrial fund aimed at enhancing its strategic development and capital cooperation in the biopharmaceutical sector [6][10]. Financial Data - The financial report for the third quarter indicates that the financial statements have not been audited [3][8]. - The company has reported significant legal disputes involving its subsidiaries, which may impact its financial standing [6][7]. Legal Disputes - A subsidiary, Baifeier, has filed a lawsuit against Shanghai Deyou Electronic Technology Co., Ltd. for a contract dispute involving a total amount of approximately 18.44 million yuan, with a breach penalty of 1.39 million yuan [6]. - The court ruled in favor of Baifeier in the first instance, ordering the return of 18.44 million yuan and a penalty of approximately 922,084.59 yuan, but the defendant has appealed [6]. - Another dispute with Shenzhen Hesheng Medical Technology Co., Ltd. involves a claim of approximately 10.34 million yuan, with the court initially ruling in favor of the company, but the case is currently under appeal [7]. Investment Activities - The company has initiated the establishment of an industrial fund, Guangzhou Zengcheng Nante Biopharmaceutical Investment Partnership, with a total investment of 50.01 million yuan, where the company contributes 25 million yuan, representing 49.99% of the total [10][11]. - The fund aims to invest in early to mid-stage biopharmaceutical projects, enhancing the company's strategic development and capital cooperation [10]. Fund Registration - The fund has completed registration with the China Securities Investment Fund Industry Association and has received the private investment fund registration certificate on October 29, 2025 [12].

Group 1 - The company, Guangzhou Jet Biofiltration Co., Ltd., will hold a half-year performance briefing on September 30, 2025, from 11:00 to 12:00 [2][5] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [3][4] - Investors can submit questions for the briefing from September 23 to September 29, 2025, through the Roadshow Center website or via the company's email [6]

Group 1 - The company has elected Ms. Dannie Yuan as the employee representative director of the fourth board of directors, effective from the date of the employee representative assembly's approval until the end of the board's term [1][2][4] - The election of the employee representative director complies with relevant laws and regulations, ensuring that the number of directors who are also senior management and employee representatives does not exceed half of the total number of directors [2][4] - Ms. Dannie Yuan holds 21,000 shares in the company and has not faced any penalties from regulatory authorities, nor does she fall under any disqualifications as per the Company Law or the company's articles of association [4] Group 2 - The company held its second extraordinary general meeting of shareholders on September 16, 2025, with all procedures and attendance complying with the Company Law and the company's articles of association [5][7][11] - All resolutions presented at the meeting were approved, including amendments to the company's articles of association and the cancellation of the supervisory board [9][10][11] - The meeting was witnessed by legal representatives from Guangdong Guangxin Junda Law Firm, confirming the legality and validity of the meeting's proceedings and resolutions [11]

Core Viewpoint - The company announces the resignation of its board secretary, Ge Jingbo, due to personal reasons, and he will no longer hold any position within the company [2][3]. Group 1: Resignation Details - Ge Jingbo submitted a written resignation report to the board, which is effective upon delivery to the board [3]. - The company confirms that Ge Jingbo has completed the handover of his responsibilities, and his resignation will not affect the normal operations of the company [3]. Group 2: Impact on the Company - The company will promptly complete the selection of a new board secretary in accordance with relevant regulations and its articles of association [3]. - Until a new board secretary is appointed, the chairman, Yuan Jianhua, will act in this capacity [3]. - Ge Jingbo did not hold any shares in the company during his tenure and was recognized for his diligent work in governance, information disclosure, and investor relations [3].

Core Points - The stock price of Jiet Biotech (688026) closed at 19.77 yuan, down 5.86% as of August 14, 2025 [1] - The company reported a total revenue of 124 million yuan for Q1 2025, representing a year-on-year growth of 26% [1] - Net profit attributable to shareholders reached 16.46 million yuan, up 101.29% year-on-year [1] - The company has a current ratio of 8.034 and a quick ratio of 6.628, indicating strong liquidity [1] Financial Performance - Total revenue for Q1 2025: 1.24 billion yuan, up 26% year-on-year [1] - Net profit: 16.46 million yuan, up 101.29% year-on-year [1] - Non-recurring net profit: 15.65 million yuan, up 269.23% year-on-year [1] - Asset-liability ratio: 28.76% [1] Company Overview - Jiet Biotech was established in 2001 and is located in Guangzhou [2] - The company focuses on research and experimental development [2] - Registered capital: 1.403 billion yuan, paid-in capital: 40 million yuan [2] - The legal representative is Yuan Jianhua [2] Investment and Intellectual Property - The company has invested in 14 enterprises and participated in 182 bidding projects [2] - It holds 79 trademark registrations and 266 patents [2] - The company has obtained 67 administrative licenses [2]

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock price performance [2][7]. Group 1: Convertible Bond Details - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB [3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and further adjusted to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025 [4]. - The downward adjustment clause is triggered when the stock price is below 85% of the conversion price for at least 15 out of 30 consecutive trading days [5]. Group 2: Board Decision - The board of directors convened on August 1, 2025, and unanimously agreed not to adjust the conversion price, with all related directors abstaining from the vote [8][9]. - The decision will remain in effect for three months, until November 1, 2025, during which time the company will not propose any downward adjustment even if the clause is triggered again [7][9].

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd, indicating a strategic move in the company's ownership structure and potential implications for future governance and investment. Group 1: Shareholder Information - The shareholder, Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership), held 1,396,950 shares, representing 1.00% of the company's total share capital prior to the reduction plan [2]. - The shares were acquired before the company's IPO and through capital reserve conversion, with the lock-up period lifted on January 30, 2023, allowing for trading [2]. Group 2: Reduction Plan Implementation - The shareholder planned to reduce holdings by up to 186,315 shares, which is 0.1327% of the total share capital, through centralized bidding [3]. - As of July 10, 2025, the shareholder successfully reduced their holdings by 186,315 shares, fully aligning with the previously disclosed reduction plan [3][4]. - The reduction was confirmed to have met the planned minimum reduction quantity, and the plan was not terminated early [4].

Summary of Key Points Core Viewpoint - The company has established a special account for the management and use of raised funds, ensuring investor protection and compliance with regulatory requirements [1][2][3]. Fundraising Basic Information - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB, which has been verified by Tianjian Accounting Firm [1]. Special Account Establishment - A special account for raised funds has been set up to temporarily supplement working capital, with a limit of 200 million RMB, effective for up to 12 months from December 30, 2024 [2][3]. Three-Party Supervision Agreement - The company signed a three-party supervision agreement with the underwriter and the bank to regulate the management of raised funds, ensuring they are used solely for designated purposes [3][4]. Regulatory Compliance - The agreement aligns with relevant laws and regulations, including the Shanghai Stock Exchange's self-regulatory guidelines, to protect investor rights [4][5]. Monitoring and Reporting - The underwriter is responsible for ongoing supervision of the fund usage, including site investigations and documentation requests, to ensure compliance with the agreement [4][5].